Ionis Pharmaceuticals Inc. (NASDAQ:IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32 • Ionis Pharmaceuticals stock is showing notable weakness. What’s pressuring IONS stock?Sales reached $203 million, beating the consensus of $156.09 million.Commercial revenue for the fourth quarter and the year ended Dec. 31, 2025, increased 64% and 49%, respectively, compared to the same periods in 2024.Tryngolza (olezarsen) product sales primarily drov ...

PresentationGood morning, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. At the podium, we have the CEO of PTC Therapeutics, Matt Klein. I'll now pass the mic to Matt for a short presentation, followed by a live audience Q&A.Matthew KleinCEO & Director Thank you, Brian, and thank you, everyone, for joining us this morning. Last year, I stood on this stage and talked about how 2025 was going ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]